Thalidomide therapy induces response in relapsed mantle cell lymphoma [7]

Leukemia

Volumn 17, Issue 9, 2003, Pages 1914-1915

  Damaj, G ^a,c   Lefrere F ^a   Delarue, R ^a   Varet, B ^a   Furman, R ^b   Hermine, O ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; MELPHALAN; PREDNISOLONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; BONE MARROW DISEASE; CANCER RECURRENCE; CASE REPORT; CONSTIPATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FATIGUE; HUMAN; INFECTION; LETTER; LYMPHADENOPATHY; MALE; MANTLE CELL LYMPHOMA; PANCYTOPENIA; PARESTHESIA; PRIORITY JOURNAL; SPLENOMEGALY; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

EID: 0141725541     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403058     Document Type: Letter

References (11)

1. Lefrere F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16: 587-593.
2. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
3. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775-779.
4. Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Lust JA et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15: 1274-1276.
5. Raje N, Anderson K. Thalidomide a revival story. N Engl J Med 1999; 341: 1606-1609.
6. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 1994; 91: 4082-4085.
7. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999; 163: 380-386.
8. Haslett PAJ, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187: 1885-1892.
9. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-216.
10. Mohty M, Stoppa AM, Blaise D, Isnardon D, Gastaut JA, Olive D et al. Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide. J Leukocute Biol 2002; 72: 939-945.
11. Keifer JA, Guttridge DC, Ashburner BP, Baldwin Jr. AS. Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity. J Biol Chem 2001; 276: 22382-22387.